
Amgen (AMGN) is slated to report its Q2 2025 earnings on August 5, with consensus estimates projecting a 5.6% year-over-year increase in both EPS to $5.25 and revenues to $8.86 billion. Despite a recent slight downward revision of 0.21% in the consensus EPS estimate, Amgen holds a positive Earnings ESP of +1.19% and a Zacks Rank #3, collectively indicating a high probability of an earnings beat. This forecast is further supported by the company's consistent record of surpassing EPS estimates in the last four consecutive quarters, positioning AMGN as a compelling earnings-beat candidate that could see near-term stock price movement based on the actual results.
Amgen (AMGN) is positioned for a potential earnings beat in its upcoming Q2 2025 report, with consensus estimates projecting year-over-year growth of 5.6% in both revenues to $8.86 billion and EPS to $5.25. While the consensus EPS estimate has seen a minor downward revision of 0.21% over the last 30 days, more recent analyst sentiment appears bullish. This is evidenced by a positive Zacks Earnings ESP (Expected Surprise Prediction) of +1.19%, which indicates that the most recent analyst estimates are higher than the broader consensus. The combination of this positive ESP and a Zacks Rank of #3 (Hold) suggests a high statistical probability of an EPS beat, a scenario further supported by Amgen's strong track record of surpassing consensus EPS estimates for the last four consecutive quarters, including a notable +17.79% surprise in the prior quarter. Despite these positive indicators, the ultimate market reaction will also depend heavily on management's forward-looking guidance provided during the earnings call.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment